Progress Toward Rationally Designed Small-Molecule Peptide and Peptidomimetic CXCR4 Antagonists

References

• Ripka AS , RichDH. Peptidomimetic design. Curr. Opin. Chem. Biol.2 (4), 441–452 (1998).
   PubMed Web of Science ®Google Scholar
• Wu B , ChienEYT, MolCDet al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science330 (6007), 1066–1071 (2010).
   PubMed Web of Science ®Google Scholar
• Qin L , KufarevaI, HoldenLGet al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science347 (6226), 1117–1122 (2015).
   PubMed Web of Science ®Google Scholar
• IUPHAR/BPS . Guide to pharmacology. www.guidetopharmacology.org.
   Google Scholar
• Luster AD . Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med.338 (7), 436–445 (1998).
   PubMed Web of Science ®Google Scholar
• Nagasawa T , NakajimaT, TachibanaKet al. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc. Natl Acad. Sci. USA93 (25), 14726–14729 (1996).
   PubMed Web of Science ®Google Scholar
• Endres MJ , ClaphamPR, MarshMet al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell87 (4), 745–756 (1996).
   PubMed Web of Science ®Google Scholar
• Lapham CK , OuyangJ, ChandrasekharB, NguyenNY, DimitrovDS, GoldingH. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science274 (5287), 602–605 (1996).
   PubMed Web of Science ®Google Scholar
• Oberlin E , AmaraA, BachelerieFet al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature382 (6594), 833–835 (1996).
   PubMed Web of Science ®Google Scholar
• Bachelerie F , Ben-BaruchA, BurkhardtAMet al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev.66 (1), 1–79 (2014).
   PubMed Web of Science ®Google Scholar
• Bajetto A , BonaviaR, BarberoS, FlorioT, CostaA, SchettiniG. Expression of chemokine receptors in the rat brain. Ann. N Y Acad. Sci.876 (1), 201–209 (1999).
   PubMedGoogle Scholar
• Han Y , WangJ, HeT, RansohoffRM. TNF-α down-regulates CXCR4 expression in primary murine astrocytes. Brain Res.888 (1), 1–10 (2001).
   PubMed Web of Science ®Google Scholar
• Barbero S , BajettoA, BonaviaRet al. Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann. N Y Acad. Sci.973 (1), 60–69 (2002).
   PubMedGoogle Scholar
• Ma Q , JonesD, BorghesaniPRet al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl Acad. Sci. USA95 (16), 9448–9453 (1998).
   PubMed Web of Science ®Google Scholar
• Scotton CJ , WilsonJL, MillikenD, StampG, BalkwillFR. Epithelial cancer cell migration: A role for chemokine receptors?Cancer Res.61 (13), 4961–4965 (2001).
   PubMed Web of Science ®Google Scholar
• Kulbe H , LevinsonNR, BalkwillF, WilsonJL. The chemokine network in cancer - much more than directing cell movement. Int. J. Dev. Biol.48 (5–6), 489–496 (2004).
   PubMed Web of Science ®Google Scholar
• Balkwill F . The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol.14 (3), 171–179 (2004).
   PubMed Web of Science ®Google Scholar
• Balkwill F . Cancer and the chemokine network. Nat. Rev. Cancer4 (7), 540–550 (2004).
   PubMed Web of Science ®Google Scholar
• Muller A , HomeyB, SotoHet al. Involvement of chemokine receptors in breast cancer metastasis. Nature410 (6824), 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Terasaki M , SugitaY, ArakawaF, OkadaY, OhshimaK, ShigemoriM. CXCL12/CXCR4 signaling in malignant brain tumors: A potential pharmacological therapeutic target. Brain Tumor Pathol.28 (2), 89–97 (2011).
   PubMed Web of Science ®Google Scholar
• Kuil J , BuckleT, Van LeeuwenFWB. Imaging agents for the chemokine receptor 4 (CXCR4). Chem. Soc. Rev.41 (15), 5239–5261 (2012).
   PubMed Web of Science ®Google Scholar
• Knight JC , WuestFR. Nuclear (PET/SPECT) and optical imaging probes targeting the CXCR4 chemokine receptor. Med. Chem. Commun.3 (9), 1039–1053 (2012).
   Google Scholar
• George GP , PisaneschiF, NguyenQD, AboagyeEO. Positron emission tomographic imaging of CXCR4 in cancer: Challenges and promises. Mol. Imaging13, 1–19 (2014).
   Google Scholar
• Larochelle A , KrouseA, MetzgerMet al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood107 (9), 3772–3778 (2006).
   PubMed Web of Science ®Google Scholar
• Masyuk M , AbduelmulaA, Morosan-PuopoloGet al. Retrograde migration of pectoral girdle muscle precursors depends on CXCR4/SDF-1 signaling. Histochem. Cell Biol.142 (5), 473–488 (2014).
   PubMed Web of Science ®Google Scholar
• Masyuk M , Brand-SaberiB. Recruitment of skeletal muscle progenitors to secondary sites: a role for CXCR4/SDF-1 signalling in skeletal muscle development. In : Vertebrate Myogenesis. Brand-SaberiB ( Ed). Springer Berlin–Heidelberg, Germany, 1–23 (2015).
   Google Scholar
• Glawe JD , MijalisEM, DavisWCet al. SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice. Diabetologia56 (10), 2222–2230 (2013).
   PubMed Web of Science ®Google Scholar
• Fujiyama T , ItoT, OgawaN, SudaT, TokuraY, HashizumeH. Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin. Exp. Immunol.177 (1), 110–120 (2014).
   PubMed Web of Science ®Google Scholar
• Wang A , GuilpainP, ChongBFet al. Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum.62 (11), 3436–3446 (2010).
   PubMedGoogle Scholar
• Launay O , PaulS, ServettazAet al. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. Vaccine31 (35), 3492–3501 (2013).
   PubMed Web of Science ®Google Scholar
• O'Brien WA , Sumner-SmithM, MaoSH, SadeghiS, ZhaoJQ, ChenIS. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol.70 (5), 2825–2831 (1996).
   PubMed Web of Science ®Google Scholar
• Doranz BJ , Grovit-FerbasK, SharronMPet al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med.186 (8), 1395–1400 (1997).
   PubMed Web of Science ®Google Scholar
• Doranz BJ , FilionLG, Diaz-MitomaFet al. Safe use of the CXCR4 inhibitor ALX40–4C in humans. AIDS Res. Hum. Retroviruses17 (6), 475–486 (2001).
   PubMed Web of Science ®Google Scholar
• Nakashima H , MasudaM, MurakamiTet al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother.36 (6), 1249–1255 (1992).
   PubMed Web of Science ®Google Scholar
• Feng Y , BroderCC, KennedyPE, BergerEA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science272 (5263), 872–877 (1996).
   PubMed Web of Science ®Google Scholar
• Murakami T , NakajimaT, KoyanagiYet al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med.186 (8), 1389–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Tamamura H , XuY, HattoriTet al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun.253 (3), 877–882 (1998).
   PubMed Web of Science ®Google Scholar
• Crump MP , GongJH, LoetscherPet al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J.16 (23), 6996–7007 (1997).
   PubMed Web of Science ®Google Scholar
• Loetscher P , GongJ-H, DewaldB, BaggioliniM, Clark-LewisI. N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J. Biol. Chem.273 (35), 22279–22283 (1998).
   PubMed Web of Science ®Google Scholar
• De Clercq E . The bicyclam AMD3100 story. Nat. Rev. Drug Discov.2 (7), 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . https://clinicaltrials.gov.
   Google Scholar
• Grande F , GarofaloA, NeamatiN. Small molecules anti-HIV therapeutics targeting CXCR4. Curr. Pharm. Des.14 (4), 385–404 (2008).
   PubMed Web of Science ®Google Scholar
• Debnath B , XuS, GrandeF, GarofaloA, NeamatiN. Small molecule inhibitors of CXCR4. Theranostics3 (1), 47–75 (2013).
   PubMed Web of Science ®Google Scholar
• Oishi S , FujiiN. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). Org. Biomol. Chem.10, 5720–5731 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang WB , NavenotJM, HaribabuBet al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40–4C are weak partial agonists. J. Biol. Chem.277 (27), 24515–24521 (2002).
   PubMed Web of Science ®Google Scholar
• Fujii N , OishiS, HiramatsuKet al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem. Int. Ed. Engl.42 (28), 3251–3253 (2003).
   PubMed Web of Science ®Google Scholar
• Kufareva I , RuedaM, KatritchV, StevensRC, AbagyanR. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure19 (8), 1108–1126 (2011).
   PubMed Web of Science ®Google Scholar
• Demarco SJ , HenzeH, LedererAet al. Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Biorg. Med. Chem.14 (24), 8396–8404 (2006).
   PubMed Web of Science ®Google Scholar
• Ruiz-Gomez G , TyndallJD, PfeifferB, AbbenanteG, FairlieDP. Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev.110 (4), PR1–PR41 (2010).
   PubMed Web of Science ®Google Scholar
• Tamamura H , SugiokaM, OdagakiYet al. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett.11 (3), 359–362 (2001).
   PubMed Web of Science ®Google Scholar
• Tamamura H , OmagariA, OishiSet al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett.10 (23), 2633–2637 (2000).
   PubMed Web of Science ®Google Scholar
• Maestro, version 10.0. Schrödinger. LLC, NY, USA (2014).
   Google Scholar
• Gerlach LO , SkerljRT, BridgerGJ, SchwartzTW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem.276 (17), 14153–14160 (2001).
   PubMed Web of Science ®Google Scholar
• Hatse S , PrincenK, VermeireKet al. Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett.546 (2–3), 300–306 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenkilde MM , GerlachL-O, JakobsenJS, SkerljRT, BridgerGJ, SchwartzTW. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: Transfer of binding site to the CXCR3 receptor. J. Biol. Chem.279 (4), 3033–3041 (2004).
   PubMed Web of Science ®Google Scholar
• Fricker SP , AnastassovV, CoxJet al. Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol.72 (5), 588–596 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenkilde MM , GerlachL-O, HatseSet al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J. Biol. Chem.282 (37), 27354–27365 (2007).
   PubMed Web of Science ®Google Scholar
• Wong RSY , BodartV, MetzM, LabrecqueJ, BridgerG, FrickerSP. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol. Pharmacol.74 (6), 1485–1495 (2008).
   PubMed Web of Science ®Google Scholar
• Cox BD , ProsserAR, KatzmanBMet al. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure. ChemBioChem15 (11), 1614–1620 (2014).
   PubMed Web of Science ®Google Scholar
• Kledal TN , RosenkildeMM, CoulinFet al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science277 (5332), 1656–1659 (1997).
   PubMed Web of Science ®Google Scholar
• Scholten DJ , CanalsM, MaussangDet al. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol.165 (6), 1617–1643 (2012).
   PubMed Web of Science ®Google Scholar
• Schwartz TW , FrimurerTM, HolstB, RosenkildeMM, EllingCE. Molecular mechanism of 7TM receptor activation – a global toggle switch model. Annu. Rev. Pharmacol. Toxicol.46 (1), 481–519 (2006).
   PubMedGoogle Scholar
• Venkatakrishnan AJ , DeupiX, LebonG, TateCG, SchertlerGF, BabuMM. Molecular signatures of G-protein-coupled receptors. Nature494 (7436), 185–194 (2013).
   PubMed Web of Science ®Google Scholar
• Manglik A , KobilkaB. The role of protein dynamics in GPCR function: Insights from the β2AR and rhodopsin. Curr. Opin. Cell Biol.27, 136–143 (2014).
   PubMed Web of Science ®Google Scholar
• Dealwis C , FernandezEJ, ThompsonDA, SimonRJ, SianiMA, LolisE. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 “fusin” coreceptor. Proc. Natl Acad. Sci. USA95 (12), 6941–6946 (1998).
   PubMed Web of Science ®Google Scholar
• Thiele S , RosenkildeMM. Interaction of chemokines with their receptors - from initial chemokine binding to receptor activating steps. Curr. Med. Chem.21 (31), 3594–3614 (2014).
   PubMed Web of Science ®Google Scholar
• Dror RO , PanAC, ArlowDHet al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl Acad. Sci. USA108 (32), 13118–13123 (2011).
   PubMed Web of Science ®Google Scholar
• Dror RO , ArlowDH, MaragakisPet al. Activation mechanism of the β2-adrenergic receptor. Proc. Natl Acad. Sci. USA108 (46), 18684–18689 (2011).
   PubMed Web of Science ®Google Scholar
• Shan J , KhelashviliG, MondalS, MehlerEL, WeinsteinH. Ligand-dependent conformations and dynamics of the serotonin 5-HT2A receptor determine its activation and membrane-driven oligomerization properties. PLoS Comput. Biol.8 (4), e1002473 (2012).
   PubMed Web of Science ®Google Scholar
• Kofuku Y , YoshiuraC, UedaTet al. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J. Biol. Chem.284 (50), 35240–35250 (2009).
   PubMed Web of Science ®Google Scholar
• Kufareva I , StephensBS, HoldenLGet al. Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation. Proc. Natl Acad. Sci. USA111 (50), E5363–E5372 (2014).
   PubMed Web of Science ®Google Scholar
• Xu L , LiY, SunH, LiD, HouT. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches. Mol. BioSyst.9 (8), 2107–2117 (2013).
   PubMedGoogle Scholar
• Tamamis P , FloudasCA. Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4. J. Chem. Inf. Model.54 (4), 1174–1188 (2014).
   PubMed Web of Science ®Google Scholar
• Veldkamp CT , SeibertC, PetersonFCet al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal.1 (37), ra4 (2008).
   PubMed Web of Science ®Google Scholar
• Costantini S , RaucciR, ColonnaGet al. Peptides targeting chemokine receptor CXCR4: Structural behavior and biological binding studies. J. Pept. Sci.20 (4), 270–278 (2014).
   PubMed Web of Science ®Google Scholar
• Klasse PJ . The molecular basis of HIV entry. Cell. Microbiol.14 (8), 1183–1192 (2012).
   PubMed Web of Science ®Google Scholar
• Huang C-C , TangM, ZhangM-Yet al. Structure of a V3-containing HIV-1 gp120 core. Science310 (5750), 1025–1028 (2005).
   PubMed Web of Science ®Google Scholar
• Huang CC , LamSN, AcharyaPet al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science317 (5846), 1930–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Tan Q , ZhuY, LiJet al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science341 (6152), 1387–1390 (2013).
   PubMed Web of Science ®Google Scholar
• Tamamis P , FloudasCA. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys. J.105 (6), 1502–1514 (2013).
   PubMed Web of Science ®Google Scholar
• Rosenkilde MM , SchwartzTW. GluVII:06 - a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr. Top. Med. Chem.6 (13), 1319–1333 (2006).
   PubMed Web of Science ®Google Scholar
• Stradley SJ , RizoJ, BruchMD, StroupAN, GieraschLM. Cyclic pentapeptides as models for reverse turns: Determination of the equilibrium distribution between type I and type II conformations of Pro-Asn and Pro-Ala beta-turns. Biopolymers29 (1), 263–287 (1990).
   PubMed Web of Science ®Google Scholar
• Marshall GR . A hierarchical approach to peptidomimetic design. Tetrahedron49 (17), 3547–3558 (1993).
   Web of Science ®Google Scholar
• Demmer O , FrankAO, HagnFet al. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew. Chem. Int. Ed. Engl.51 (32), 8110–8113 (2012).
   PubMed Web of Science ®Google Scholar
• Tamamura H , ArakiT, UedaSet al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem.48 (9), 3280–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Tamamura H , HiramatsuK, UedaSet al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem.48 (2), 380–391 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda S , OishiS, WangZXet al. Structure–activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: Disclosing the importance of side-chain and backbone functionalities. J. Med. Chem.50 (2), 192–198 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi K , OishiS, HayashiRet al. Structure–activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres. J. Med. Chem.55 (6), 2746–2757 (2012).
   PubMed Web of Science ®Google Scholar
• Tamamura H , MizumotoM, HiramatsuKet al. Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org. Biomol. Chem.2 (8), 1255–1257 (2004).
   PubMed Web of Science ®Google Scholar
• Narumi T , HayashiR, TomitaKet al. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Org. Biomol. Chem.8 (3), 616–621 (2010).
   PubMed Web of Science ®Google Scholar
• Narumi T , TomitaK, InokuchiEet al. Diastereoselective synthesis of highly functionalized fluoroalkene dipeptide isosteres and its application to Fmoc-based solid-phase synthesis of a cyclic pentapeptide mimetic. Tetrahedron64 (19), 4332–4346 (2008).
   Web of Science ®Google Scholar
• Inokuchi E , OishiS, KuboTet al. Potent CXCR4 antagonists containing amidine type peptide bond isosteres. ACS Med. Chem. Lett.2 (6), 477–480 (2011).
   PubMed Web of Science ®Google Scholar
• Tanaka T , NomuraW, NarumiTet al. Structure–activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: The exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids. Org. Biomol. Chem.7 (18), 3805–3809 (2009).
   PubMed Web of Science ®Google Scholar
• Mungalpara J , ThieleS, EriksenØ, EksteenJ, RosenkildeMM, Våben⊘J. Rational design of conformationally constrained cyclopentapeptide antagonists for C-X-C chemokine receptor 4 (CXCR4). J. Med. Chem.55 (22), 10287–10291 (2012).
   PubMed Web of Science ®Google Scholar
• Tamamura H , EsakaA, OgawaTet al. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org. Biomol. Chem.3 (24), 4392–4394 (2005).
   PubMed Web of Science ®Google Scholar
• Mungalpara J , ZachariassenZG, ThieleS, RosenkildeMM, Våben⊘J. Structure–activity relationship studies of the aromatic positions in cyclopentapeptide CXCR4 antagonists. Org. Biomol. Chem.11, 8202–8208 (2013).
   PubMed Web of Science ®Google Scholar
• Tanaka T , TsutsumiH, NomuraWet al. Structure–activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: Identification of the new pharmacophore. Org. Biomol. Chem.6 (23), 4374–4377 (2008).
   PubMed Web of Science ®Google Scholar
• Våben⊘ J , NikiforovichGV, MarshallGR. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists. Biopolymers84 (5), 459–471 (2006).
   PubMed Web of Science ®Google Scholar
• Demmer O , DijkgraafI, SchumacherUet al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J. Med. Chem.54 (21), 7648–7662 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y , KobayashiK, OishiS, FujiiN, FuruyaT. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4-FC131 interactions. Bioorg. Med. Chem. Lett.22 (6), 2146–2150 (2012).
   PubMed Web of Science ®Google Scholar
• Thiele S , MungalparaJ, SteenA, RosenkildeMM, Våben⊘J. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. Br. J. Pharmacol.171 (23), 5313–5329 (2014).
   PubMed Web of Science ®Google Scholar
• Tamamura H , TsutsumiH, MasunoHet al. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org. Biomol. Chem.4 (12), 2354–2357 (2006).
   PubMed Web of Science ®Google Scholar
• Ichiyama K , Yokoyama-KumakuraS, TanakaYet al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA100 (7), 4185–4190 (2003).
   PubMed Web of Science ®Google Scholar
• Tamamura H , HiramatsuK, MizumotoMet al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org. Biomol. Chem.1 (21), 3663–3669 (2003).
   PubMed Web of Science ®Google Scholar
• Narumi T , TanakaT, HashimotoCet al. Pharmacophore-based small molecule CXCR4 ligands. Bioorg. Med. Chem. Lett.22 (12), 4169–4172 (2012).
   PubMed Web of Science ®Google Scholar
• Cluzeau J , OishiS, OhnoHet al. Design and synthesis of all diastereomers of cyclic pseudo-dipeptides as mimics of cyclic CXCR4 pentapeptide antagonists. Org. Biomol. Chem.5 (12), 1915–1923 (2007).
   PubMed Web of Science ®Google Scholar
• Garland Marshall: US20050192272 (2005).
   Google Scholar
• Niida A , TanigakiH, InokuchiEet al. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2′ reactions and their use in the preparation of low-molecule CXCR4 antagonists. J. Org. Chem.71 (10), 3942–3951 (2006).
   PubMed Web of Science ®Google Scholar
• Ueda S , KatoM, InukiSet al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg. Med. Chem. Lett.18 (14), 4124–4129 (2008).
   PubMed Web of Science ®Google Scholar
• Zachariassen ZG , ThieleS, BergEAet al. Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4). Biorg. Med. Chem.22 (17), 4759–4769 (2014).
   PubMed Web of Science ®Google Scholar
• Murakami T , KumakuraS, YamazakiTet al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: Comparative studies with AMD3100. Antimicrob. Agents Chemother.53 (7), 2940–2948 (2009).
   PubMed Web of Science ®Google Scholar
• Iwasaki Y , AkariH, MurakamiTet al. Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci.100 (4), 778–781 (2009).
   PubMed Web of Science ®Google Scholar
• Mosley CA , WilsonLJ, WisemanJM, SkudlarekJW, LiottaDC. Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin. Ther. Pat.19 (1), 23–38 (2009).
   PubMed Web of Science ®Google Scholar
• Portella L , VitaleR, De LucaSet al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PloS ONE8 (9), e74548 (2013).
   PubMed Web of Science ®Google Scholar
• Cojoc M , PeitzschC, TrautmannF, PolishchukL, TelegeevGD, DubrovskaA. Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. OncoTargets Ther.6, 1347 (2013).
   PubMedGoogle Scholar
• Chatterjee S , Behnam AzadB, NimmagaddaS. The intricate role of CXCR4 in cancer. Adv. Cancer Res.124, 31–82 (2014).
   PubMed Web of Science ®Google Scholar
• Mysinger MM , WeissDR, ZiarekJJet al. Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc. Natl Acad. Sci. USA109 (14), 5517–5522 (2012).
   PubMed Web of Science ®Google Scholar
• Vitale RM , GattiM, CarboneMet al. Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine A as a new CXCR4 ligand exhibiting antagonist activity. ACS Chem. Biol.8 (12), 2762–2770 (2013).
   PubMed Web of Science ®Google Scholar